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Several polymorphisms in the Disrupted-in-Schizophrenia-1 (DISC1) gene are reported to be
associated with schizophrenia. However, to date, there has been little effort to evaluate the
evidence for association systematically. We carried out an imputation-driven meta-analysis,
the most comprehensive to date, using data collected from 10 candidate gene studies and
three genome-wide association studies containing a total of 11626 cases and 15237 controls.
We tested 1241 single-nucleotide polymorphisms in total, and estimated that our power to
detect an effect from a variant with minor allele frequency >5% was 99% for an odds ratio of
1.5 and 51% for an odds ratio of 1.1. We find no evidence that common variants at the DISC1
locus are associated with schizophrenia.
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Introduction
Schizophrenia is a debilitating psychiatric illness
with a lifetime prevalence of around 0.4%
1 and a
heritability estimated to be between 80 and 85%.
2,3
One schizophrenia susceptibility gene that has
attracted much attention is Disrupted-in-Schizophre-
nia-1 (DISC1). DISC1 is one of the three genes (with
DISC2 and TSNAX) lying at the site of a balanced
t(1;11)(q42.1;q14.3) translocation, which has a strong
association (logarithm of the odds ratio=7.1) with
schizophrenia and other mental illness in a large
Scottish pedigree.
4,5
Further evidence that DISC1 genetic variants pre-
dispose to schizophrenia in particular comes from
four sources. First, the expression of the protein
product DISC1 is reduced in the Scottish pedigree in
which the translocation segregates. Second, DISC1
interacts physically with PDE4B. Another Scottish
family with schizophrenia has a translocation that
reduces the expression of PDE4B.
6 Third, association
between schizophrenia and variants at the DISC1
locus has been reported.
7–20 Fourth, sequencing part
of the DISC1 gene in 288 cases identified six rare
coding variants not found in 10000 controls.
21
These findings, along with evidence of DISC1’s
involvement in other mental illnesses including
bipolar disorder,
19 depression
11 and autism,
22 have
spurred research into understanding what DISC1 does
in the brain. Studies of DISC1’s interactome have
revealed that it is involved in synaptic development
pathways
23 and interacts with proteins important for
neural development such as NDEL1.
24–26 These
results seem promising for DISC1’s role in schizo-
phrenia in light of the common hypothesis that the
origin of the condition is neurodevelopmental.
However, there has been no comprehensive meta-
analysis of schizophrenia association study findings
for DISC1, despite the fact that the association
evidence is not totally consistent. Association has
been reported over almost the entire gene (Figure 1;
refs.
7–20), but the largest study to date failed to
detect any association,
27 and genome-wide associa-
tion studies (GWAS) have not found a clear signal
at DISC1.
Meta-analysis of DISC1 findings is difficult to carry
out because the gene is large (414kb) and includes
many variants (2603 single-nucleotide polymorph-
isms (SNPs) in single-nucleotide polymorphism
database (dbSNP) 131). There is no consensus about
which markers have the strongest association, no
markers are tested in all studies and most are tested in
only a small number of studies. Therefore, we
decided to try to combine data from studies that use
different markers by imputation. This method esti-
mates results from a marker that has not been
genotyped by exploiting linkage disequilibrium with
markers that have been genotyped.
Until recently, there was insufficient sequence
information at the DISC1 locus to make imputation
feasible; however, release of data from phase 3 of the
International HapMap project
28 and from the first
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29 provide the most comprehen-
sive catalog of common human genetic variation
available today, including rare variants. We set out
to use these publicly available data to impute
genotypes in DISC1 association studies and to
combine results from all available sources, including
both GWAS and candidate gene studies, thus over-
coming the problems described above.
Methods
Selection of studies for inclusion
We identified candidate gene studies and GWAS for
schizophrenia or schizoaffective disorder in unrelated
case–control samples drawn from populations of
predominantly European ancestry with at least 100
cases and controls. Studies reporting data on both
male and female cases and controls were included.
We did not include studies where data from multiple
individuals was pooled and analyzed together. We
excluded studies where the samples overlapped
significantly with another identified study.
Systematic literature search
We considered all studies listed for DISC1 on the
SZGene database.
30 We also searched PubMed with
the search terms ‘DISC1’ AND ‘Schizophrenia’ AND
‘Association’ and also for the terms ‘Schizophrenia’
AND ‘GWAS’. Once these had been collected, their
bibliographies were then searched for additional
references. The abstracts of studies thus identified
were examined with respect to the inclusion criteria
above. Studies failing to meet the criteria were
discarded, and the full text of remaining studies was
examined to determine whether or not they should be
included.
Data extraction
For each study, the following data were extracted: (1)
author(s) and year of publication; (2) sample size; and
(3) data (individual genotypes, genotype counts or
minor allele frequencies (MAFs) in order of prefer-
ence). Where the required data were not available in
the published study or from web-based supplemen-
tary information, we contacted the authors of the
paper by email to request access to the data. For
GWAS, we requested data for the region extending
100kb upstream of DISC1 and downstream of TSNAX
(Chr1: 231572000–232277000 in the hg19 genome
assembly), which covers all reported associations.
Quality control
In addition to any quality control performed by the
authors of the studies, we excluded any SNPs that
failed the following tests: (1) MAF in cases or controls
<0.01. (2) Where alleles were given in the study data,
we checked them against dbSNP alleles
31 and ex-
cluded the SNP if the reported alleles differed from
the dbSNP alleles and could not be explained by a
strand flip. We also excluded the SNP if no alleles
were specified in the study data and the MAF was
>0.45; otherwise, we coded the SNP by the minor
allele. (3) For studies where we had genotype counts
available, we excluded SNPs that had a Hardy–
Weinberg equilibrium test P-value of <0.001.
Imputation
One of the problems encountered in previous
attempts at meta-analysis is the lack of overlap
Figure 1 Reported Disrupted-in-Schizophrenia-1 (DISC1) associations including both family and association studies from
populations of all ethnicities and indicating regions reported as being significantly associated with schizophrenia.
7–20 These
includes family-based linkage studies and studies in non-European populations, which were not included in this study. The
numbers to the right of the graph indicate numbers of cases/controls in the study.
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dressed this problem by imputing genotypes for
studies where we had full genotype data. Imputation
was carried out using IMPUTE v.2,
32,33 with reference
panels of CEU haplotypes from HapMap 3 and the
1000 Genomes pilot 1. The CEU haplotypes are taken
from samples from the Centre d’Etude du Polymor-
phisme Humain collected from individuals living in
Utah, USA, with ancestry from northern and western
Europe. The haplotype data were obtained from the
IMPUTE website (http://mathgen.stats.ox.ac.uk/
impute/impute.html). For studies where we did not
have full genotype data (we had genotype counts or
MAFs), we imputed MAFs using the linear predictor
implemented in the BLIMP package
34 and the CEU
haplotypes from 1000 Genomes pilot 1. We attempted
to impute for all studies that genotyped at more than
10 SNPs.
Size and power calculations
To calculate the size and power of the meta-analysis,
we simulated case–control data from haplotypes
drawn from the 1000 Genomes pilot 1. To calculate
the P-value required to obtain a given significance
level, we sampled data from the 1000 Genomes
haplotypes, with the same characteristics as the
studies in the sample (numbers of cases, controls
and testing the same SNPs), calculated effect sizes
and P-values as described below and obtained the
empirical significance levels for each SNP. We
repeated the simulation and determined the required
nominal point-wise significance level required to
achieve a gene-wide significance level of 0.05.
To calculate the power of the meta-analysis, we
again sampled from the 1000 Genomes data with the
same characteristics as the meta-analysis samples, but
in each simulation, we chose a SNP at random and
weighted the sampling probabilities in cases to ensure
that the chosen SNP had a specified odds ratio (OR) in
cases relative to controls. We performed the analysis
as described below and recorded whether the sig-
nificance level determined above was reached by any
SNP. The proportion of tests with any SNP reaching
significance gave us an estimate of the power of
the meta-analysis for a given effect size. For size
calculations, we performed 10000 simulations,
and for power calculations, we performed 1000 per
data point.
Statistical analysis
Log-ORs (equivalent to logistic regression coeffi-
cients) and their standard deviations were calculated
for each SNP in each study and then combined across
studies using fixed and random effects models.
35 We
tested whether any of the pooled P-values were more
significant than the thresholds calculated above. We
also tested whether the distribution of P-values
differed significantly from that expected under the
null hypothesis. For each SNP, we investigated
whether there was any evidence for heterogeneity
using the I
2 statistic.
36
For the imputed genotypes, we calculated the test
statistics using SNPTEST,
32 which takes into account
the genotype uncertainty generated by the imputa-
tion. For imputed allele frequencies, we calculated
the proportion of the genotypic variance explained by
the imputation, and filtered out any SNP where this
was below 80%. We then calculated test statistics as
for the original data. These were then combined with
the test statistics from genotyped SNPs as above. We
considered separately: (1) the genotyped data; (2) the
genotyped data plus the imputed data, but considered
only loci that were genotyped in at least one study;
and (3) the genotyped data plus all the imputed data.
We removed each study from the meta-analysis in
turn to determine whether any single study had a
disproportionate effect on the analysis. We also
calculated Wakefield approximate Bayes factors
37
from estimates of the standardized effect sizes and
their variances, assuming a prior for the effect size
that was normally distributed with mean 0 and
variance 0.015. This prior is equivalent to the belief
that for each SNP, there is a 95% probability that its
OR lies between 0.79 and 1.28.
Results
We obtained data for 11 candidate gene studies and
four GWAS containing a total of 11626 cases and
15237 controls (Table 1). We could not obtain data
from one case–control study and one GWAS matching
our criteria because there was no response from the
authors. Three studies were excluded because they
overlapped substantially with other studies (Table 2).
The total number of separate SNPs genotyped in any
study was 401.
Imputation dramatically increased the number of
studies testing each SNP. Before imputation, 100
SNPs were tested in a single study only. After
imputation, there were only 13 such SNPs. The mean
number of studies testing each SNP increased from
2.6 to 4.3, if only sites genotyped in a single study
were considered, and to 3.4 if all imputed sites were
used. Ultimately, we obtained data on a total of 1241
separate SNPs. Many of the SNPs in the full imputed
data set were tested in only two studies and were
heavily dependent on the International Schizophre-
nia Consortium data.
38
For testing the 401 genotyped loci, we used a point-
wise significance level of 1.9210
4 corresponding
to a gene-wide significance level of 0.05. We gener-
ated this threshold by simulation, using the exact
SNPs and sample sizes available in the included
studies. It is equivalent to a multiple testing correc-
tion for 260 (95% confidence interval 250–269)
independent tests. For the 1241 SNPs in the imputed
data, the correction is equivalent to 444 independent
tests (95% confidence interval 424–467). With these
cutoffs, we estimated that for common variants (MAF
>5%), the power to detect a true association at
OR=1.5, with the imputed data restricted to geno-
typed loci was 99%. For OR=1.1 the power was 51%.
DISC1 not associated with schizophrenia
I Mathieson et al
636
Molecular PsychiatryFor rare variants, power is much lower. For variants
with MAF between 1 and 5%, the corresponding
figures are 92 and 6%. For variants with MAF below
1%, which we did not try to test, the power is very
low, even for high ORs. These figures are the power to
detect an association at any locus given the OR at the
causal locus, which is not necessarily the one
detected. Figure 2 shows power as a function of
MAF for different ORs at the causal allele.
Using these significance thresholds, we detected
no significant association with any tested SNP
(Figures 3 and 4). The most associated SNP was
rs1765805, 160kb upstream of DISC1 (P=610
4,
genotyped in 1860 cases and 2389 controls), but this
was heavily dependent on a single study
38 and not
supported by nearby SNPs. The next highest associa-
tions were found in the regions of rs1331046
(P=1.410
3, imputed in 3610 cases and 3938
controls), downstream of the gene, and rs17817356
(P=710
3, genotyped in 4405 cases and 7427
controls, imputed in 2291 cases and 2293 controls),
between exons 6 and 7, and about 30kb upstream
from DISC2. Like rs1765805, the association at
rs1331046 was driven by the ISC data, but the
association at rs17817356 was supported by the ISC
and other data sets as well. In the random effects
analysis, the associations at rs1765805 and
rs17817356 remained at the same significance level,
but the association at rs1331046 was substantially
reduced (P>0.03).
Excluding the ISC study significantly altered our
results, and was the only study whose omission did
so. As noted above, the associations at rs1765085 and
rs1331046 were supported only by the ISC. However,
this may be because few other studies tested these
SNPs. Both SNPs are outside the gene, in a region
where we had lower coverage, as most candidate gene
studies have concentrated on SNPs inside the gene.
To assess heterogeneity, we calculated the I
2
statistic for all SNPs. This was zero for the majority
(70%) of loci and distributed between 0 and 80% for
the rest. Tests of heterogeneity are generally under-
powered when, as here, there are few studies,
39,40 so
we cannot make conclusive statements about the
Table 1 Details of studies analyzed
SNPs tested
Study Year Gen Imp Cases Controls
Devon et al.
CM 53 2001 3 0 656 344
Hodgkinson et al.
CF 14 2004 38 62 242 213
Wood et al.
CF 54 2007 74 328 451 291
Song et al.
CS 21 2008 3 0 288 288
Saetre et al.
CS 17 2008 15 52 837 1473
Sanders et al.
CF 27 2008 114 521 1870 2002
O’Donovan et al.
GM 55 2008 115 180 478 2937
Betcheva et al.
CM 56 2009 14 46 255 556
Hennah et al.
CS 12 2009 62 136 1263 1275
Rastogi et al.
CS 16 2009 9 0 210 210
Schumacher et al.
CM 18 2009 108 210 782 839
Need et al.
GS 57 2009 72 138 673 871
ISC et al.
GF 38 2009 224 832 3322 3587
Athanasiu et al.
GF 58 2010 250 955 298 351
Abbreviations: C, candidate gene(s); F, full genotypes; G,
genome-wide association studies; Gen, genotyped; Imp,
imputed; M, minor allele frequencies; S, summary geno-
types; SNP, single-nucleotide polymorphism.
Table 2 Studies that met our inclusion criteria, but which were not included
Study Year Reason for exclusion
Thomson et al.
19 2005 Samples reported in Hennah et al.
12
Zhang et al.
20 2006 Samples partially reported in Hennah et al.
12
Lencz et al.
59 2007 Samples reported in Hodgkinson et al.
14
Nicodemus et al.
60 2007 No response from author
a
Stefansson et al.
61 2009 No response from author
b
‘No response from author’ refers to email response to the corresponding author, specifically.
aWe received an initial response, but no response to two further emails.
bNo response after three initial emails.
Figure 2 Estimated power as a function of minor allele
frequency at the causal allele, showing results for different
odds ratios. The power was simulated using variants and
haplotypes from the 1000 Genomes data and the curves
have been fitted as smooth splines of degree 6.
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that most genetic associations display between-study
heterogeneity
41 and that fixed and random effects
models give the same results when there is no
heterogeneity, it seems prudent to use the more
conservative random effects model to estimate effect
size or to prioritize markers for further analysis.
Using the effects estimated by the random effects
model, the approximate Bayes factors reveal a similar
pattern to the P-values (Figure 5), and indicate that
the region around rs17817356 has the most evidence
in favor of association and that there is no consistent
evidence for association elsewhere in the gene.
There are three commonly tested non-synonymous
SNPs in the gene, rs3738401, rs821616 and
rs6675281. The variants rs821616 and rs6675281 have
been reported to have functional effects, affecting
centrosomal PCM1 localization,
42,43 expression of
splice variants,
44 hippocampal function
45 and inter-
action with NDEL1, which is important for neurite
outgrowth.
46 However, we detected no significant
associations at any of these SNPs (P=0.11, 0.51 and
0.93 in the raw data and 0.49, 0.60 and 0.28 in the
imputed).
Given the potential contribution of rare variants in
DISC1 to schizophrenia risk, we searched additional
sources of data to identify further functional variants
not represented in dbSNP. In the 1000 Genomes pilot
data, we found one additional non-synonymous
coding SNP. We also looked in the results from a
recent exome sequencing study of 200 Danish
individuals
47 and identified five novel non-synon-
ymous SNPs. Of these six variants, two had been
discovered in cases and controls by Song et al.
21 and
four were novel (Table 3).
Discussion
We have carried out a comprehensive analysis of
candidate schizophrenia susceptibility variants in the
DISC1 gene. We found no significant association with
any variant. We calculated approximate Bayes factors
for each SNP to identify the regions where there was
Figure 5 Wakefield approximate Bayes factors for each
single-nucleotide polymorphism (SNP). Calculated from the
random effects pooled P-values and Z-scores assuming a
normal prior on the log-OR, with mean 0 and variance of
0.015. A Bayes factor >0 is evidence for association,
whereas a Bayes factor <0 is evidence against.
Figure 3 Pooled P-values for association. Each point
represents a single-nucleotide polymorphism (SNP). The
horizontal axis indicates chromosomal position, and the
vertical axis indicates negative log10 of the fixed-effect
pooled P-value for that SNP. The black points show the
imputed SNPs and the gray points show the subset of the
imputed SNPs, which were genotyped in at least one study.
The horizontal dashed lines show the corrected significance
level, which is equivalent to a 5% gene-wide significance
level for each data set.
Figure 4 Quantile–quantile (QQ) plot of P-values. QQ plot
of the P-values shown in Figure 2. The solid line shows the
expected values under the null hypothesis of no association
and the dashed lines show the upper and lower 95%
quantiles.
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evidence of association was in a region between exons
6 and 7. Our meta-analysis had to deal with the
problem that of 401 variants reported in the literature,
120 markers were tested in a single study and a
further 110 in just two studies. The lack of overlap in
the markers tested in different studies poses a
challenge to meta-analysis that we overcame by
imputing genotypes. By combining results from
genome-wide association and candidate gene studies
together with LD data from the HapMap and 1000
Genomes projects, we were able to test the involve-
ment of 1241 SNPs in a combined sample of 11626
cases and 15237 controls.
Our results raise four questions. First, what range of
effects have we tested? Second, to what extent have
we excluded the involvement of common variants
throughout the gene? Third, can we draw any
conclusions about the role of rare variants at the
DISC1 locus? Finally, why have we been unable to
replicate the many previously reported associations?
Power calculations help to answer the first question
(Figure 2). Power depends critically on the sample
size, which is not straightforward to estimate.
Although the total number of cases and controls in
our sample was 11626 and 15237, not every SNP was
tested in every individual. In the raw data, the mean
numbers of cases and controls testing any single SNP
were 2781 and 3782. We cannot directly calculate the
sample sizes for the imputed data as we used imputed
genotype probabilities in our tests, but comparison of
the variance of test statistics suggests that the mean
improvement was equivalent to increasing the sample
size by 49% to a mean of 4144 cases and 5653
controls. These figures are heavily skewed in the
sense that some variants have much larger sample
sizes. Imputation also allowed us to test variants that
had not been genotyped in any study.
Our power calculations are only approximate as we
sampled from a fairly limited set of haplotypes.
However, they can give us an indication of what
effects we have tested. For variants with MAF >5%,
we had 99% power to detect an effect with OR=1.5
and 51% power to detect an effect with OR=1.1.
However, it is possible that effects will be too small to
detect, even for high-frequency variants. Robust
association for common variants with OR of <1.1
have been reported in a study of height
48 and it is not
inconceivable that similarly small effects operate in
schizophrenia.
49 It has been argued that such variants
can explain a significant proportion of the heritability
for common diseases and traits.
38,49,50
Results from the HapMap and 1000 Genomes
projects provide an answer to the second question.
Genotyped SNPs included 32% of all SNPs with
MAF >5% in the 1000 Genomes, and imputed SNPs
included 89%. For SNPs with MAF between 1 and
5%, the corresponding figures are 10 and 41%. For
genotyped loci, 95% of the gene is within 5.0kb of a
tested SNP, 50% is within 1.4kb and the maximum
distance without a tested SNP is 13.7kb. For the
imputed data, the figures are 2.6, 0.6 and 7.2kb. These
small regions make it unlikely that any common SNP
could exist that we have not, at least indirectly, tested.
Third, the effects may arise from alleles too rare to
be tested here. It is not surprising that common
variants do not have a large effect on susceptibility to
such a debilitating disease, but we might expect rare
variants to have larger effects. Although we tested
variants down to an MAF of 1%, we had very low
power at this level, and we could not even test all the
known variants of this frequency. Further stages of the
1000 Genomes project will allow most variants at this
frequency to be tested. On the other hand, association
between DISC1 and the disease might derive from
extremely rare, essentially private, mutations of large
effect.
51,52 One study reported the identification of
coding mutations in schizophrenia cases that were
not detected in 10000 control subjects.
21 However,
this study did not search in healthy controls for rare
variants that were not found in cases. In two studies
sampling 260 individuals in total, we found four
novel non-synonymous mutations, and rediscovered
two that had been identified in the previous study.
This suggests that coding mutations in DISC1 may be
more common in healthy individuals than previously
assumed. However, it should also be noted that
control subjects were not actively screened for the
absence of schizophrenia, a family history of schizo-
phrenia or related mental illnesses.
Finally, many previous studies have reported
association. There are a number of reasons why we
might have failed to replicate these results; publica-
tion bias, winner’s curse, allelic heterogeneity and
population, sex or subgroup-specific heterogeneity.
We have not attempted to investigate these here, but it
is worth noting that the presence of heterogeneity of
effects would particularly tend to confound large
GWAS and meta-analyses such as this one.
Our meta-analysis does not address the question of
DISC1’s involvement in other mental illness, such as
bipolar disorder, major depressive disorder or autism
spectrum disorder, nor does it answer all the ques-
tions with regard to the association of DISC1 with
schizophrenia. Although we found no significant
Table 3 Non-synonymous SNPs not found in dbSNP
identified in 260 individuals
Position
(hg18)
NT
substitution
AA
substitution
Source Song
et al.?
229896375 C/T A83V 47 Yes
229896606 G/T W160L 47 No
229896987 C/T P287L 47 No
229897063 T/G C312W 47 No
229969594 T/C I452F 47 No
230969594 A/T E751Q 29 Yes
Abbreviation: AA, amino acid; dbSNP, single-nucleotide
polymorphism database; NT, nucleotide. Two have been
found in a previous study and four are novel.
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Molecular Psychiatryassociation with common variants, many studies have
reported sex-specific and interaction effects,
9,11,12,18,19
which we did not test. Consideration of the power
required to detect such effects suggests that if they do
exist, significantly larger studies will be required to
detect them convincingly. For example, if we were to
test all pairwise SNP–SNP interactions for all im-
puted SNPs in this study, we would be increasing the
multiple testing factor by around 100000. We would
also be reducing the sample size for each test,
particularly for combinations of rare variants, making
it difficult, if not impossible, to reach statistical
significance. Hypothesis-driven tests derived from
functional studies and model systems may prove
more productive than data mining in this case.
Whatever the true effect of the factors described
above, it seems likely that we will need to consider
new study designs and new statistical techniques to
further investigate the effect of DISC1 variation on
schizophrenia and other psychiatric illnesses.
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